Endocrinology & Diabetes

Diabetes Therapeutics and Diagnostics

The incidence rate of diabetes is exceptionally high across the world, fueled by reducing physical activities and unhealthy diet. Consistent with IMARC’s report, compared to Type-1 diabetes, Type-2 diabetes represents the more prevalent type, accounting for the bulk of all diagnosed diabetes cases. Urban areas dominate rural areas within the number of diabetes patients and females presently account for the bulk of the entire diabetes patients. Despite the overall down climate of the economy and healthcare, there has been great progress within the advancement of diabetes knowledge, treatment and prevention in recent years. This progress continues of a day to day, with scientific advances being announced at an exponential rate. New therapeutic products are being introduced regularly and therefore the pipeline is now filled with new diabetes therapeutics in development. Never before, within the history of drugs, has the outlook for diabetes treatment and prevention looked so promising. The diabetes drugs segment dominated the endocrinology drugs market and accounted for quite 86% of the market share during 2015. At an annual rate of growth (CAGR) of 4.4%, from 2016 to 2021, World diabetes market projected to succeed in $155 billion by 2021 from $125 billion.